Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
Maria João SousaLorenzo GervasoMonica Isabel Meneses-MedinaFrancesca SpadaOmar Abdel-RahmanNicola FazioPublished in: Current oncology reports (2022)
Preclinical results showed a promising antitumor activity of CDK4/6 inhibitors in neuroendocrine tumors (NETs), but so far, the very few small clinical trials did not show a strong impact on progression free survival (PFS) and objective response in NETs. Meanwhile, the CDK4/6 inhibitor trilaciclib revealed significant effects in reducing chemotherapy-induced myelosuppression in small cell lung cancer (SCLC). Up to date, CDK4/6 inhibitors are still considered investigational in NETs as antitumor agents, whereas trilaciclib can be used in the routine clinical practice in extensive stage SCLC patients for reducing myelotoxicity of standard chemotherapy.
Keyphrases
- cell cycle
- clinical practice
- small cell lung cancer
- chemotherapy induced
- free survival
- clinical trial
- neuroendocrine tumors
- end stage renal disease
- ejection fraction
- cell proliferation
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- phase ii
- cell therapy
- radiation therapy
- open label
- locally advanced